Spironolactone Management in Cirrhosis with Pedal Edema

Initial Dosing and Titration

• Start spironolactone at 100 mg once daily, titrating upward to a maximum of 400 mg/day while checking electrolytes and renal function within the first week and at regular intervals thereafter. 1
• Spironolactone is the primary diuretic for cirrhotic ascites and peripheral edema, acting as an aldosterone antagonist that counteracts secondary hyperaldosteronism. 2
• Recommended starting dose is 50–100 mg once daily, with most guidelines favoring the 100 mg dose. 3
• Give the dose in the morning as a single administration to accommodate its long half‑life (3–4 days to steady state) and to minimize nocturia. 4
• In patients with peripheral edema, no strict daily weight‑loss limit is imposed; clinicians should use judgment to set an appropriate rate. 5
• In patients without peripheral edema, limit weight loss to ≤0.5 kg per day to avoid intravascular volume depletion. 6
• If response is inadequate (weight loss < 0.5 kg/day or persistent symptoms), increase the dose by 100 mg every 3–5 days. 3
• Maximum allowable dose is 400 mg/day. 7
• Because of the drug’s long half‑life, allow at least 72 hours between dose adjustments. 3

Combination with Loop Diuretics

• Adding furosemide (initially or sequentially) enhances natriuresis and helps maintain normokalemia. 8
• An initial combination of spironolactone 100 mg + furosemide 40 mg provides faster ascites control and lowers hyper‑kalemia risk compared with spironolactone alone, especially in recurrent or moderate‑to‑large ascites. 4
• Sequential addition of furosemide is appropriate for out‑patients with mild ascites or when a conservative start is desired. 8
• Maintain a 100 : 40 spironolactone‑to‑furosemide ratio to preserve normokalemia. 4
• Furosemide starting dose: 20–40 mg/day; maximum dose: 160 mg/day. 6

Monitoring Parameters

• Serum potassium, sodium, creatinine, body weight, and vital signs should be checked within 1 week of initiation or any dose change, then monitored regularly. 3
• Potassium > 5.5 mmol/L → halve the spironolactone dose. 7
• Potassium > 6.0 mmol/L → stop spironolactone immediately and treat hyperkalemia. 7
• Potassium < 3.0 mmol/L → reduce or discontinue furosemide. 7
• Sodium < 125 mmol/L → reduce or stop diuretics and consider fluid restriction. 2
• Sodium < 120 mmol/L despite fluid restriction → stop diuretics and reassess. 8
• Creatinine rise > 0.3 mg/dL within 48 h or ≥ 1.5‑fold within 1 week → reduce or stop diuretics. 5

Indications to Reduce or Discontinue Spironolactone

• Severe hyponatremia (serum sodium < 120–125 mmol/L). 9
• Acute kidney injury as defined by creatinine criteria above. 7
• Overt hepatic encephalopathy without other precipitating factors. 5
• Severe muscle cramps. 3
• Symptomatic hypotension. 9

Dietary and Lifestyle Adjuncts

• Sodium restriction to ≤ 2 g/day (≈ 88 mmol or 5 g salt). 4
• Refer patients to a dietitian for education on label reading, cooking methods, and to ensure adequate protein (1.2–1.5 g/kg/day) and calories (≥ 35 kcal/kg/day). 4
• Fluid restriction is unnecessary unless hyponatremia is present. 4
• 24‑hour urine sodium > 88 mmol/day signals dietary indiscretion. 3
• Spot urine Na⁺/K⁺ ratio > 1 suggests adequate natriuresis; if weight loss is absent, suspect non‑compliance. 3

Adverse Effects and Management

• Gynecomastia occurs in ≈ 9–14 % of male patients, dose‑dependent, with onset from 1 month to > 1 year. 10
• If painful gynecomastia develops, switch to amiloride (10–40 mg/day) or eplerenone (50–100 mg/day); these agents are less effective than spironolactone. 3

Refractory Ascites

• Definition: Ascites that does not respond to maximum diuretic therapy (spironolactone 400 mg + furosemide 160 mg) for ≥ 1 week on a salt‑restricted diet (< 5 g/day), with mean weight loss < 800 g over 4 days and urinary sodium output less than intake. 5
• In refractory cases, consider large‑volume paracentesis with albumin replacement (6–8 g albumin per liter of fluid removed). 7
• Discontinue diuretics when urinary sodium excretion falls below 30 mmol/day in diuretic‑resistant ascites. 1

Spironolactone Initiation and Monitoring in Cirrhotic Patients with Elevated Creatinine

Indications and Patient Selection

• In cirrhotic patients with ascites, spironolactone may be started at 50–100 mg daily only if serum creatinine is ≤ 2.5 mg/dL and serum potassium is < 5.0 mmol/L; laboratory tests must be repeated within 3–7 days, and the drug should be reduced or stopped if creatinine rises acutely or potassium exceeds 5.5 mmol/L. 11

Initial Dosing Strategy

• The standard initial dose is 100 mg once daily for most cirrhotic patients with ascites, administered in the morning. [11][12]
• An alternative 50 mg daily start is reasonable for patients with borderline renal function (creatinine 1.5–2.5 mg/dL), borderline potassium (4.5–5.0 mmol/L), or advanced age. (cited in guideline)

Combination with Loop Diuretics

• Adding furosemide 40 mg at the start of therapy leads to faster ascites mobilization and better maintenance of normokalemia compared with spironolactone alone. [11][12]
• When combination therapy is used, maintain a spironolactone : furosemide ratio of 100 : 40 during dose escalation to preserve potassium balance. 12
• In out‑patient settings with mild ascites, a sequential approach (spironolactone first, furosemide added only if needed) is acceptable. 12

Dose Titration and Maximum Limits

• If weight loss is < 0.5 kg/day without peripheral edema, increase spironolactone by 100 mg every 3–5 days. 12
• The maximum recommended dose is 400 mg/day of spironolactone together with 160 mg/day of furosemide. [11][12]
• Allow at least 72 hours between dose adjustments because spironolactone reaches steady state after 3–4 days.

Monitoring Protocol

• Serum potassium, sodium, and creatinine should be checked within 3–7 days of initiation or any dose change. 11
• After the initial check, repeat labs at 1 week, then weekly for the first month, followed by monthly monitoring for the first 3 months and thereafter every 3–6 months if stable. 11
• Daily body weight should be recorded to guide diuretic dosing. 12

Thresholds for Dose Reduction or Discontinuation

• Potassium 5.5–6.0 mmol/L: reduce spironolactone dose by 50 % (e.g., from 100 mg to 50 mg daily).
• Potassium ≥ 6.0 mmol/L: stop spironolactone immediately and treat hyperkalemia.
• Serum sodium < 125 mmol/L: reduce or stop diuretics and restrict fluid intake to 1–1.5 L/day. 11

Adverse Event Frequency

• Approximately 50 % of patients on diuretics experience adverse events that require dose adjustment or discontinuation. 11

Management of Refractory Ascites

• Refractory ascites is defined as failure to achieve adequate fluid removal despite maximum diuretic doses (spironolactone 400 mg + furosemide 160 mg), a low‑sodium diet (< 5 g/day), and a mean weight loss < 800 g over 4 days.
• Large‑volume paracentesis with albumin replacement (6–8 g albumin per litre of fluid removed) is the first‑line therapy. 11
• Candidates for transjugular intra‑hepatic portosystemic shunt (TIPS) should be ≤ 70 years old, have bilirubin < 50 µmol/L, platelet count > 75 × 10⁹/L, MELD score < 18, and no active hepatic encephalopathy. 11

Alternative Agents for Gynecomastia

• Gynecomastia occurs in 9–14 % of male patients on spironolactone and is dose‑dependent.
• If painful gynecomastia develops, switching to amiloride (10–40 mg/day) or eplerenone (50–100 mg/day) is recommended; eplerenone 100 mg/day is equally effective for ascites mobilization and has not been associated with gynecomastia. 12

Spironolactone Initiation, Dosing, and Monitoring in Cirrhosis with Renal Impairment

Indications and Initial Dosing

• In patients with cirrhosis and borderline renal function (serum creatinine ≈ 1.5–2.5 mg/dL), start spironolactone at 50 mg once daily; this lower dose reduces hyper‑kalemia risk while maintaining efficacy. 13
• The usual starting dose range is 50–100 mg daily; clinicians should prefer the lower end when creatinine is elevated or potassium is near the upper normal limit. 13

Pharmacokinetic Considerations

• Spironolactone has a long half‑life of 3–4 days; therefore dose adjustments should be spaced by at least 72 hours to allow steady‑state concentrations to be reached. 13

Combination with Loop Diuretics

• Initiate furosemide at 40 mg daily together with spironolactone to achieve faster ascites control and help maintain normokalemia. 13
• During dose escalation, keep a 100 mg spironolactone : 40 mg furosemide ratio to balance natriuretic effects and limit potassium rise. 13
• Adding furosemide reduces the risk of hyperkalemia compared with spironolactone monotherapy, especially in patients with recurrent or moderate‑to‑large ascites. 13

Monitoring Protocol

• Laboratory checks (serum potassium, sodium, and creatinine) should be performed 3–7 days after therapy initiation or any dose change. 13
• Continue weekly labs for the first month, then monthly for the next three months to detect early electrolyte or renal deterioration. 13
• Record daily body weight to guide diuretic titration and assess fluid removal effectiveness. 13

Thresholds for Dose Reduction or Discontinuation

Hyperkalemia

• Potassium 5.5–6.0 mmol/L – halve the spironolactone dose (e.g., 50 mg → 25 mg daily or every other day). 13
• Potassium ≥ 6.0 mmol/L – stop spironolactone immediately and treat the hyperkalemia. 13

Acute Kidney Injury (AKI)

• Creatinine rise > 0.3 mg/dL (≈27 µmol/L) within 48 h or ≥ 1.5‑fold increase within 1 week – reduce or stop diuretics. 13
• Creatinine > 2.5 mg/dL (≈221 µmol/L) – discontinue spironolactone. 13
• The American Association for the Study of Liver Diseases (AASLD) defines diuretic‑intractable ascites as renal impairment with a > 100 % creatinine increase to > 2.0 mg/dL. (Guideline recommendation) 14

Hyponatremia

• Serum sodium < 125 mmol/L – reduce or stop diuretics and consider fluid restriction to 1–1.5 L/day. 13
• Serum sodium < 120 mmol/L despite restriction – stop diuretics and reassess volume status. 13

Other Indications to Stop

• Development of overt hepatic encephalopathy without other precipitating factors. 13
• Severe muscle cramps or symptomatic hypotension. 13

Dietary and Lifestyle Adjuncts

• Advise dietary sodium restriction to ≤ 2 g/day (≈88 mmol or 5 g salt). (Expert recommendation) 13
• Target weight loss of ~0.5 kg/day (up to 1 kg/day if peripheral edema is present) to achieve effective fluid removal. (Expert recommendation) 13

Safety Considerations and Common Pitfalls

• Do not discontinue spironolactone for mild hyperkalemia (5.0–5.5 mmol/L) without first attempting dose reduction and correcting reversible causes. 13
• Do not assume hyperkalemia is always drug‑related; evaluate for heart‑failure decompensation, progressive kidney disease, or dietary excess. 13
• Avoid intravenous diuretics in cirrhosis; oral administration is standard because IV use can cause abrupt fluid shifts and AKI. (Expert recommendation) 13
• Loop diuretics should not be used as monotherapy; aldosterone antagonists remain the cornerstone of diuretic therapy in cirrhosis. (Expert recommendation) 13

Management of Gynecomastia

• Gynecomastia occurs in 9–14 % of male patients on spironolactone and is dose‑dependent. (Expert observation) 13
• If painful gynecomastia develops, switch to amiloride (10–40 mg/day) or eplerenone (50–100 mg/day); eplerenone 100 mg/day provides ascites control comparable to spironolactone without causing gynecomastia. (Expert recommendation) 13
• Amiloride offers a weaker diuretic effect but has minimal anti‑androgen activity, making it a suitable alternative for patients intolerant to spironolactone‑related endocrine side effects. (Expert recommendation) 13

Refractory Ascites Management (AASLD Guidelines)

• Refractory ascites is defined as failure to achieve adequate fluid removal despite maximum diuretic doses (spironolactone 400 mg + furosemide 160 mg) for ≥ 1 week on a salt‑restricted diet (< 5 g/day), with mean weight loss < 800 g over 4 days and urinary sodium excretion less than intake. (Guideline definition) 14
• The first‑line therapy for refractory ascites is large‑volume paracentesis with albumin replacement (6–8 g albumin per liter of fluid removed). (Guideline recommendation) 14
• Discontinue diuretics when urinary sodium excretion falls below 30 mmol/day in diuretic‑resistant ascites. (Expert recommendation) 14